PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
申请人:Genentech, Inc.
公开号:EP3670514A1
公开(公告)日:2020-06-24
A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
式 I 的化合物、对映体、二映体、同系物或其药学上可接受的盐,其中 R1、R2 和 R3 在本文中定义,可用作一种或多种 Janus 激酶的抑制剂。本发明公开了一种药物组合物,该组合物包括式 I 的化合物和药学上可接受的载体、佐剂或载体,以及治疗或减轻对抑制患者 Janus 激酶活性有反应的疾病或病症的方法。
TOMITORI, EMIKO;OKAMOTO, TOSHIHIKO, J. PHARM. SOC. JAP., 1984, 104, N 11, 1122-1132